Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimab Group AB's revenue for the
three
months ended in Mar. 2026 was kr67.5 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr325.7 Mil.
Vimab Group AB's Revenue per Share for the
three
months ended in Mar. 2026 was kr1.56.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr11.35.
Warning Sign:
Vimab Group AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Vimab Group AB was -13.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -19.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -33.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -20.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Vimab Group AB's highest 3-Year average Revenue per Share Growth Rate was 36.80% per year. The lowest was -42.90% per year. And the median was -7.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Vimab Group AB Revenue Related Terms
Vimab Group AB Revenue Historical Data
* Premium members only.
The historical data trend for Vimab Group AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Consulting Services subindustry, Vimab Group AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimab Group AB Revenue vs Business Services Industry
For the Business Services industry and Industrials sector, Vimab Group AB's Revenue distribution charts can be found below:
* The bar in red indicates where Vimab Group AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr325.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimab Group AB (OSTO:VIMAB) has a Revenue of kr325.7 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Vimab Group AB and its competitors.
Is Vimab Group AB's Revenue too high?
Vimab Group AB's current Revenue is kr325.7 Mil. Overall, Vimab Group AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vimab Group AB's Revenue compare to VRSK and EFX?
Vimab Group AB's Revenue of kr325.7 Mil can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Business Services company?
A good Revenue depends on the Business Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Vimab Group AB and its competitors. Vimab Group AB's current Revenue is kr325.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimab Group AB stock overvalued right now?
Based on GuruFocus' analysis, Vimab Group AB (OSTO:VIMAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr5.95, compared to a current price of kr2.89 — trading 51.4% below its estimated fair value. The current Revenue is kr325.7 Mil. Vimab Group AB's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Vimab Group AB (OSTO:VIMAB), the current Revenue is kr325.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimab Group AB (OSTO:VIMAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vimab Group AB stock appears to be undervalued.
The current stock price of kr2.89 is trading 51.4% below its estimated GF Value™ of kr5.95.
GuruFocus considers Vimab Group AB to be Possible Value Trap.
Key valuation signals for OSTO:VIMAB:
Revenue: kr325.7 Mil
GF Value™: kr5.95 vs. price of kr2.89 (51.4% below fair value)
No single metric tells the full story. See the OSTO:VIMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimab Group AB is a Nordic company helping companies with transformation and improvement initiatives. It offers services including Interim management, Executive search.
47GF Score
Get the complete analysis for OSTO:VIMAB
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VIMAB has been successfully added to your 
